カテゴリー： Market Monitor Global, 世界, 医療/バイオ

閉経後骨粗鬆症治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Post Menopausal Osteoporosis Drug Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8588 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：104 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Post Menopausal Osteoporosis Drug Market 調査レポートは次の情報を含め、グローバルにおけるの閉経後骨粗鬆症治療薬市場規模と予測を収録しています。・世界の閉経後骨粗鬆症治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の閉経後骨粗鬆症治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の閉経後骨粗鬆症治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「経口式」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

閉経後骨粗鬆症治療薬のグローバル主要企業は、Amgen Inc、 Ipsen SA、 Aryogen Pharmed Co、 Lupin Ltd、 Celltrion Inc、 Clayton Biotechnologies Inc、 Hualan Biological Engineering Inc、 Fresenius Kabi SwissBioSim GmbH、 Genor BioPharma Co Ltd、 InSight Biopharmaceuticals Ltd、 Eden Biologics Inc、 Enteris BioPharma Inc、 Ablynx NV、 Hengenix Biotech Inc、 Luye Pharma Group Ltd、 Intas Pharmaceuticals Ltd、 Metabolab Inc、 Jiangsu Hansoh Pharmaceutical Group Co Ltd、 Jiangsu T-mab BioPharma Co Ltdなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、閉経後骨粗鬆症治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の閉経後骨粗鬆症治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の閉経後骨粗鬆症治療薬市場：タイプ別市場シェア、2022年
・経口式、皮下注射、静脈注射、その他

世界の閉経後骨粗鬆症治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の閉経後骨粗鬆症治療薬市場：用途別市場シェア、2022年
・病院、診療所、その他

世界の閉経後骨粗鬆症治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の閉経後骨粗鬆症治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における閉経後骨粗鬆症治療薬のグローバル売上、2018年-2023年
・主要企業における閉経後骨粗鬆症治療薬のグローバル売上シェア、2022年
・主要企業における閉経後骨粗鬆症治療薬のグローバル販売量、2018年-2023年
・主要企業における閉経後骨粗鬆症治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Amgen Inc、 Ipsen SA、 Aryogen Pharmed Co、 Lupin Ltd、 Celltrion Inc、 Clayton Biotechnologies Inc、 Hualan Biological Engineering Inc、 Fresenius Kabi SwissBioSim GmbH、 Genor BioPharma Co Ltd、 InSight Biopharmaceuticals Ltd、 Eden Biologics Inc、 Enteris BioPharma Inc、 Ablynx NV、 Hengenix Biotech Inc、 Luye Pharma Group Ltd、 Intas Pharmaceuticals Ltd、 Metabolab Inc、 Jiangsu Hansoh Pharmaceutical Group Co Ltd、 Jiangsu T-mab BioPharma Co Ltd

*************************************************************

・調査・分析レポートの概要
閉経後骨粗鬆症治療薬市場の定義
市場セグメント
世界の閉経後骨粗鬆症治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の閉経後骨粗鬆症治療薬市場規模
世界の閉経後骨粗鬆症治療薬市場規模：2022年 VS 2029年
世界の閉経後骨粗鬆症治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの閉経後骨粗鬆症治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の閉経後骨粗鬆症治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：経口式、皮下注射、静脈注射、その他
閉経後骨粗鬆症治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
閉経後骨粗鬆症治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別閉経後骨粗鬆症治療薬市場規模 2022年と2029年
地域別閉経後骨粗鬆症治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Amgen Inc、 Ipsen SA、 Aryogen Pharmed Co、 Lupin Ltd、 Celltrion Inc、 Clayton Biotechnologies Inc、 Hualan Biological Engineering Inc、 Fresenius Kabi SwissBioSim GmbH、 Genor BioPharma Co Ltd、 InSight Biopharmaceuticals Ltd、 Eden Biologics Inc、 Enteris BioPharma Inc、 Ablynx NV、 Hengenix Biotech Inc、 Luye Pharma Group Ltd、 Intas Pharmaceuticals Ltd、 Metabolab Inc、 Jiangsu Hansoh Pharmaceutical Group Co Ltd、 Jiangsu T-mab BioPharma Co Ltd
...

This report aims to provide a comprehensive presentation of the global market for Post Menopausal Osteoporosis Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Post Menopausal Osteoporosis Drug. This report contains market size and forecasts of Post Menopausal Osteoporosis Drug in global, including the following market information:
Global Post Menopausal Osteoporosis Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Post Menopausal Osteoporosis Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Oral Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Post Menopausal Osteoporosis Drug include Amgen Inc, Ipsen SA, Aryogen Pharmed Co, Lupin Ltd, Celltrion Inc, Clayton Biotechnologies Inc, Hualan Biological Engineering Inc, Fresenius Kabi SwissBioSim GmbH and Genor BioPharma Co Ltd, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Post Menopausal Osteoporosis Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Post Menopausal Osteoporosis Drug Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Post Menopausal Osteoporosis Drug Market Segment Percentages, by Type, 2022 (%)
Oral
Subcutaneous
Intravenous Injection
Others
Global Post Menopausal Osteoporosis Drug Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Post Menopausal Osteoporosis Drug Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Post Menopausal Osteoporosis Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Post Menopausal Osteoporosis Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Post Menopausal Osteoporosis Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Post Menopausal Osteoporosis Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen Inc
Ipsen SA
Aryogen Pharmed Co
Lupin Ltd
Celltrion Inc
Clayton Biotechnologies Inc
Hualan Biological Engineering Inc
Fresenius Kabi SwissBioSim GmbH
Genor BioPharma Co Ltd
InSight Biopharmaceuticals Ltd
Eden Biologics Inc
Enteris BioPharma Inc
Ablynx NV
Hengenix Biotech Inc
Luye Pharma Group Ltd
Intas Pharmaceuticals Ltd
Metabolab Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu T-mab BioPharma Co Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of Post Menopausal Osteoporosis Drug, market overview.
Chapter 2: Global Post Menopausal Osteoporosis Drug market size in revenue.
Chapter 3: Detailed analysis of Post Menopausal Osteoporosis Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Post Menopausal Osteoporosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Post Menopausal Osteoporosis Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Post Menopausal Osteoporosis Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Post Menopausal Osteoporosis Drug Overall Market Size
2.1 Global Post Menopausal Osteoporosis Drug Market Size: 2022 VS 2029
2.2 Global Post Menopausal Osteoporosis Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Post Menopausal Osteoporosis Drug Players in Global Market
3.2 Top Global Post Menopausal Osteoporosis Drug Companies Ranked by Revenue
3.3 Global Post Menopausal Osteoporosis Drug Revenue by Companies
3.4 Top 3 and Top 5 Post Menopausal Osteoporosis Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Post Menopausal Osteoporosis Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Post Menopausal Osteoporosis Drug Players in Global Market
3.6.1 List of Global Tier 1 Post Menopausal Osteoporosis Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Post Menopausal Osteoporosis Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Post Menopausal Osteoporosis Drug Market Size Markets, 2022 & 2029
4.1.2 Oral
4.1.3 Subcutaneous
4.1.4 Intravenous Injection
4.1.5 Others
4.2 By Type – Global Post Menopausal Osteoporosis Drug Revenue & Forecasts
4.2.1 By Type – Global Post Menopausal Osteoporosis Drug Revenue, 2018-2023
4.2.2 By Type – Global Post Menopausal Osteoporosis Drug Revenue, 2024-2029
4.2.3 By Type – Global Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Post Menopausal Osteoporosis Drug Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application – Global Post Menopausal Osteoporosis Drug Revenue & Forecasts
5.2.1 By Application – Global Post Menopausal Osteoporosis Drug Revenue, 2018-2023
5.2.2 By Application – Global Post Menopausal Osteoporosis Drug Revenue, 2024-2029
5.2.3 By Application – Global Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Post Menopausal Osteoporosis Drug Market Size, 2022 & 2029
6.2 By Region – Global Post Menopausal Osteoporosis Drug Revenue & Forecasts
6.2.1 By Region – Global Post Menopausal Osteoporosis Drug Revenue, 2018-2023
6.2.2 By Region – Global Post Menopausal Osteoporosis Drug Revenue, 2024-2029
6.2.3 By Region – Global Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Post Menopausal Osteoporosis Drug Revenue, 2018-2029
6.3.2 US Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.3.3 Canada Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.3.4 Mexico Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Post Menopausal Osteoporosis Drug Revenue, 2018-2029
6.4.2 Germany Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.4.3 France Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.4.4 U.K. Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.4.5 Italy Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.4.6 Russia Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.4.7 Nordic Countries Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.4.8 Benelux Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Post Menopausal Osteoporosis Drug Revenue, 2018-2029
6.5.2 China Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.5.3 Japan Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.5.4 South Korea Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.5.5 Southeast Asia Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.5.6 India Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Post Menopausal Osteoporosis Drug Revenue, 2018-2029
6.6.2 Brazil Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.6.3 Argentina Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Post Menopausal Osteoporosis Drug Revenue, 2018-2029
6.7.2 Turkey Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.7.3 Israel Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Post Menopausal Osteoporosis Drug Market Size, 2018-2029
6.7.5 UAE Post Menopausal Osteoporosis Drug Market Size, 2018-2029
7 Post Menopausal Osteoporosis Drug Companies Profiles
7.1 Amgen Inc
7.1.1 Amgen Inc Company Summary
7.1.2 Amgen Inc Business Overview
7.1.3 Amgen Inc Post Menopausal Osteoporosis Drug Major Product Offerings
7.1.4 Amgen Inc Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.1.5 Amgen Inc Key News & Latest Developments
7.2 Ipsen SA
7.2.1 Ipsen SA Company Summary
7.2.2 Ipsen SA Business Overview
7.2.3 Ipsen SA Post Menopausal Osteoporosis Drug Major Product Offerings
7.2.4 Ipsen SA Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.2.5 Ipsen SA Key News & Latest Developments
7.3 Aryogen Pharmed Co
7.3.1 Aryogen Pharmed Co Company Summary
7.3.2 Aryogen Pharmed Co Business Overview
7.3.3 Aryogen Pharmed Co Post Menopausal Osteoporosis Drug Major Product Offerings
7.3.4 Aryogen Pharmed Co Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.3.5 Aryogen Pharmed Co Key News & Latest Developments
7.4 Lupin Ltd
7.4.1 Lupin Ltd Company Summary
7.4.2 Lupin Ltd Business Overview
7.4.3 Lupin Ltd Post Menopausal Osteoporosis Drug Major Product Offerings
7.4.4 Lupin Ltd Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.4.5 Lupin Ltd Key News & Latest Developments
7.5 Celltrion Inc
7.5.1 Celltrion Inc Company Summary
7.5.2 Celltrion Inc Business Overview
7.5.3 Celltrion Inc Post Menopausal Osteoporosis Drug Major Product Offerings
7.5.4 Celltrion Inc Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.5.5 Celltrion Inc Key News & Latest Developments
7.6 Clayton Biotechnologies Inc
7.6.1 Clayton Biotechnologies Inc Company Summary
7.6.2 Clayton Biotechnologies Inc Business Overview
7.6.3 Clayton Biotechnologies Inc Post Menopausal Osteoporosis Drug Major Product Offerings
7.6.4 Clayton Biotechnologies Inc Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.6.5 Clayton Biotechnologies Inc Key News & Latest Developments
7.7 Hualan Biological Engineering Inc
7.7.1 Hualan Biological Engineering Inc Company Summary
7.7.2 Hualan Biological Engineering Inc Business Overview
7.7.3 Hualan Biological Engineering Inc Post Menopausal Osteoporosis Drug Major Product Offerings
7.7.4 Hualan Biological Engineering Inc Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.7.5 Hualan Biological Engineering Inc Key News & Latest Developments
7.8 Fresenius Kabi SwissBioSim GmbH
7.8.1 Fresenius Kabi SwissBioSim GmbH Company Summary
7.8.2 Fresenius Kabi SwissBioSim GmbH Business Overview
7.8.3 Fresenius Kabi SwissBioSim GmbH Post Menopausal Osteoporosis Drug Major Product Offerings
7.8.4 Fresenius Kabi SwissBioSim GmbH Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.8.5 Fresenius Kabi SwissBioSim GmbH Key News & Latest Developments
7.9 Genor BioPharma Co Ltd
7.9.1 Genor BioPharma Co Ltd Company Summary
7.9.2 Genor BioPharma Co Ltd Business Overview
7.9.3 Genor BioPharma Co Ltd Post Menopausal Osteoporosis Drug Major Product Offerings
7.9.4 Genor BioPharma Co Ltd Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.9.5 Genor BioPharma Co Ltd Key News & Latest Developments
7.10 InSight Biopharmaceuticals Ltd
7.10.1 InSight Biopharmaceuticals Ltd Company Summary
7.10.2 InSight Biopharmaceuticals Ltd Business Overview
7.10.3 InSight Biopharmaceuticals Ltd Post Menopausal Osteoporosis Drug Major Product Offerings
7.10.4 InSight Biopharmaceuticals Ltd Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.10.5 InSight Biopharmaceuticals Ltd Key News & Latest Developments
7.11 Eden Biologics Inc
7.11.1 Eden Biologics Inc Company Summary
7.11.2 Eden Biologics Inc Business Overview
7.11.3 Eden Biologics Inc Post Menopausal Osteoporosis Drug Major Product Offerings
7.11.4 Eden Biologics Inc Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.11.5 Eden Biologics Inc Key News & Latest Developments
7.12 Enteris BioPharma Inc
7.12.1 Enteris BioPharma Inc Company Summary
7.12.2 Enteris BioPharma Inc Business Overview
7.12.3 Enteris BioPharma Inc Post Menopausal Osteoporosis Drug Major Product Offerings
7.12.4 Enteris BioPharma Inc Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.12.5 Enteris BioPharma Inc Key News & Latest Developments
7.13 Ablynx NV
7.13.1 Ablynx NV Company Summary
7.13.2 Ablynx NV Business Overview
7.13.3 Ablynx NV Post Menopausal Osteoporosis Drug Major Product Offerings
7.13.4 Ablynx NV Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.13.5 Ablynx NV Key News & Latest Developments
7.14 Hengenix Biotech Inc
7.14.1 Hengenix Biotech Inc Company Summary
7.14.2 Hengenix Biotech Inc Business Overview
7.14.3 Hengenix Biotech Inc Post Menopausal Osteoporosis Drug Major Product Offerings
7.14.4 Hengenix Biotech Inc Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.14.5 Hengenix Biotech Inc Key News & Latest Developments
7.15 Luye Pharma Group Ltd
7.15.1 Luye Pharma Group Ltd Company Summary
7.15.2 Luye Pharma Group Ltd Business Overview
7.15.3 Luye Pharma Group Ltd Post Menopausal Osteoporosis Drug Major Product Offerings
7.15.4 Luye Pharma Group Ltd Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.15.5 Luye Pharma Group Ltd Key News & Latest Developments
7.16 Intas Pharmaceuticals Ltd
7.16.1 Intas Pharmaceuticals Ltd Company Summary
7.16.2 Intas Pharmaceuticals Ltd Business Overview
7.16.3 Intas Pharmaceuticals Ltd Post Menopausal Osteoporosis Drug Major Product Offerings
7.16.4 Intas Pharmaceuticals Ltd Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.16.5 Intas Pharmaceuticals Ltd Key News & Latest Developments
7.17 Metabolab Inc
7.17.1 Metabolab Inc Company Summary
7.17.2 Metabolab Inc Business Overview
7.17.3 Metabolab Inc Post Menopausal Osteoporosis Drug Major Product Offerings
7.17.4 Metabolab Inc Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.17.5 Metabolab Inc Key News & Latest Developments
7.18 Jiangsu Hansoh Pharmaceutical Group Co Ltd
7.18.1 Jiangsu Hansoh Pharmaceutical Group Co Ltd Company Summary
7.18.2 Jiangsu Hansoh Pharmaceutical Group Co Ltd Business Overview
7.18.3 Jiangsu Hansoh Pharmaceutical Group Co Ltd Post Menopausal Osteoporosis Drug Major Product Offerings
7.18.4 Jiangsu Hansoh Pharmaceutical Group Co Ltd Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.18.5 Jiangsu Hansoh Pharmaceutical Group Co Ltd Key News & Latest Developments
7.19 Jiangsu T-mab BioPharma Co Ltd
7.19.1 Jiangsu T-mab BioPharma Co Ltd Company Summary
7.19.2 Jiangsu T-mab BioPharma Co Ltd Business Overview
7.19.3 Jiangsu T-mab BioPharma Co Ltd Post Menopausal Osteoporosis Drug Major Product Offerings
7.19.4 Jiangsu T-mab BioPharma Co Ltd Post Menopausal Osteoporosis Drug Revenue in Global Market (2018-2023)
7.19.5 Jiangsu T-mab BioPharma Co Ltd Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Post Menopausal Osteoporosis Drug Market Opportunities & Trends in Global Market
Table 2. Post Menopausal Osteoporosis Drug Market Drivers in Global Market
Table 3. Post Menopausal Osteoporosis Drug Market Restraints in Global Market
Table 4. Key Players of Post Menopausal Osteoporosis Drug in Global Market
Table 5. Top Post Menopausal Osteoporosis Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Post Menopausal Osteoporosis Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Post Menopausal Osteoporosis Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Post Menopausal Osteoporosis Drug Product Type
Table 9. List of Global Tier 1 Post Menopausal Osteoporosis Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Post Menopausal Osteoporosis Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Post Menopausal Osteoporosis Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Post Menopausal Osteoporosis Drug Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Post Menopausal Osteoporosis Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Post Menopausal Osteoporosis Drug Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Post Menopausal Osteoporosis Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Post Menopausal Osteoporosis Drug Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2024-2029
Table 30. Amgen Inc Company Summary
Table 31. Amgen Inc Post Menopausal Osteoporosis Drug Product Offerings
Table 32. Amgen Inc Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 33. Amgen Inc Key News & Latest Developments
Table 34. Ipsen SA Company Summary
Table 35. Ipsen SA Post Menopausal Osteoporosis Drug Product Offerings
Table 36. Ipsen SA Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 37. Ipsen SA Key News & Latest Developments
Table 38. Aryogen Pharmed Co Company Summary
Table 39. Aryogen Pharmed Co Post Menopausal Osteoporosis Drug Product Offerings
Table 40. Aryogen Pharmed Co Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 41. Aryogen Pharmed Co Key News & Latest Developments
Table 42. Lupin Ltd Company Summary
Table 43. Lupin Ltd Post Menopausal Osteoporosis Drug Product Offerings
Table 44. Lupin Ltd Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 45. Lupin Ltd Key News & Latest Developments
Table 46. Celltrion Inc Company Summary
Table 47. Celltrion Inc Post Menopausal Osteoporosis Drug Product Offerings
Table 48. Celltrion Inc Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 49. Celltrion Inc Key News & Latest Developments
Table 50. Clayton Biotechnologies Inc Company Summary
Table 51. Clayton Biotechnologies Inc Post Menopausal Osteoporosis Drug Product Offerings
Table 52. Clayton Biotechnologies Inc Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 53. Clayton Biotechnologies Inc Key News & Latest Developments
Table 54. Hualan Biological Engineering Inc Company Summary
Table 55. Hualan Biological Engineering Inc Post Menopausal Osteoporosis Drug Product Offerings
Table 56. Hualan Biological Engineering Inc Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 57. Hualan Biological Engineering Inc Key News & Latest Developments
Table 58. Fresenius Kabi SwissBioSim GmbH Company Summary
Table 59. Fresenius Kabi SwissBioSim GmbH Post Menopausal Osteoporosis Drug Product Offerings
Table 60. Fresenius Kabi SwissBioSim GmbH Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 61. Fresenius Kabi SwissBioSim GmbH Key News & Latest Developments
Table 62. Genor BioPharma Co Ltd Company Summary
Table 63. Genor BioPharma Co Ltd Post Menopausal Osteoporosis Drug Product Offerings
Table 64. Genor BioPharma Co Ltd Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 65. Genor BioPharma Co Ltd Key News & Latest Developments
Table 66. InSight Biopharmaceuticals Ltd Company Summary
Table 67. InSight Biopharmaceuticals Ltd Post Menopausal Osteoporosis Drug Product Offerings
Table 68. InSight Biopharmaceuticals Ltd Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 69. InSight Biopharmaceuticals Ltd Key News & Latest Developments
Table 70. Eden Biologics Inc Company Summary
Table 71. Eden Biologics Inc Post Menopausal Osteoporosis Drug Product Offerings
Table 72. Eden Biologics Inc Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 73. Eden Biologics Inc Key News & Latest Developments
Table 74. Enteris BioPharma Inc Company Summary
Table 75. Enteris BioPharma Inc Post Menopausal Osteoporosis Drug Product Offerings
Table 76. Enteris BioPharma Inc Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 77. Enteris BioPharma Inc Key News & Latest Developments
Table 78. Ablynx NV Company Summary
Table 79. Ablynx NV Post Menopausal Osteoporosis Drug Product Offerings
Table 80. Ablynx NV Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 81. Ablynx NV Key News & Latest Developments
Table 82. Hengenix Biotech Inc Company Summary
Table 83. Hengenix Biotech Inc Post Menopausal Osteoporosis Drug Product Offerings
Table 84. Hengenix Biotech Inc Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 85. Hengenix Biotech Inc Key News & Latest Developments
Table 86. Luye Pharma Group Ltd Company Summary
Table 87. Luye Pharma Group Ltd Post Menopausal Osteoporosis Drug Product Offerings
Table 88. Luye Pharma Group Ltd Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 89. Luye Pharma Group Ltd Key News & Latest Developments
Table 90. Intas Pharmaceuticals Ltd Company Summary
Table 91. Intas Pharmaceuticals Ltd Post Menopausal Osteoporosis Drug Product Offerings
Table 92. Intas Pharmaceuticals Ltd Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 93. Intas Pharmaceuticals Ltd Key News & Latest Developments
Table 94. Metabolab Inc Company Summary
Table 95. Metabolab Inc Post Menopausal Osteoporosis Drug Product Offerings
Table 96. Metabolab Inc Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 97. Metabolab Inc Key News & Latest Developments
Table 98. Jiangsu Hansoh Pharmaceutical Group Co Ltd Company Summary
Table 99. Jiangsu Hansoh Pharmaceutical Group Co Ltd Post Menopausal Osteoporosis Drug Product Offerings
Table 100. Jiangsu Hansoh Pharmaceutical Group Co Ltd Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 101. Jiangsu Hansoh Pharmaceutical Group Co Ltd Key News & Latest Developments
Table 102. Jiangsu T-mab BioPharma Co Ltd Company Summary
Table 103. Jiangsu T-mab BioPharma Co Ltd Post Menopausal Osteoporosis Drug Product Offerings
Table 104. Jiangsu T-mab BioPharma Co Ltd Post Menopausal Osteoporosis Drug Revenue (US$, Mn) & (2018-2023)
Table 105. Jiangsu T-mab BioPharma Co Ltd Key News & Latest Developments
List of Figures
Figure 1. Post Menopausal Osteoporosis Drug Segment by Type in 2022
Figure 2. Post Menopausal Osteoporosis Drug Segment by Application in 2022
Figure 3. Global Post Menopausal Osteoporosis Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Post Menopausal Osteoporosis Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Post Menopausal Osteoporosis Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Post Menopausal Osteoporosis Drug Revenue in 2022
Figure 8. By Type - Global Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 9. By Application - Global Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 10. By Type - Global Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 12. By Application - Global Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 14. By Region - Global Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 15. By Country - North America Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 16. US Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 20. Germany Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 21. France Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 28. China Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 32. India Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 34. Brazil Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Post Menopausal Osteoporosis Drug Revenue Market Share, 2018-2029
Figure 37. Turkey Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Post Menopausal Osteoporosis Drug Revenue, (US$, Mn), 2018-2029
Figure 41. Amgen Inc Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Ipsen SA Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Aryogen Pharmed Co Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Lupin Ltd Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Celltrion Inc Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Clayton Biotechnologies Inc Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Hualan Biological Engineering Inc Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Fresenius Kabi SwissBioSim GmbH Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Genor BioPharma Co Ltd Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. InSight Biopharmaceuticals Ltd Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Eden Biologics Inc Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Enteris BioPharma Inc Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Ablynx NV Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Hengenix Biotech Inc Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Luye Pharma Group Ltd Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Intas Pharmaceuticals Ltd Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Metabolab Inc Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Jiangsu Hansoh Pharmaceutical Group Co Ltd Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. Jiangsu T-mab BioPharma Co Ltd Post Menopausal Osteoporosis Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

※参考情報

閉経後骨粗鬆症は、主に女性において閉経後のホルモンバランスの変化によって引き起こされる骨密度の減少を特徴とする疾病です。特にエストロゲンの減少は骨代謝に大きな影響を及ぼし、骨密度の低下を招きます。その結果、骨が脆くなり、骨折のリスクが増加します。骨粗鬆症の治療が必要とされるのは、この骨折リスクを軽減するためです。

閉経後骨粗鬆症治療薬は、骨密度を増加させたり、骨の破壊を抑制したりすることで、骨折リスクを軽減することを目的としています。これらの薬剤は、骨代謝に関与する様々なメカニズムを標的としています。主な治療薬の種類としては、ビスフォスフォネート、選択的エストロゲン受容体モジュレーター（SERM）、骨形成促進薬、ホルモン療法、抗RANKL抗体などがあります。

ビスフォスフォネートは、最も一般的に使用される骨粗鬆症治療薬です。このクラスの薬剤は、骨吸収を抑制することで骨密度を維持し、骨折リスクを低下させます。アルンドロン酸やリセドロン酸などの製剤が含まれ、経口投与および静脈内投与が可能です。ビスフォスフォネートは、長期使用における安全性が高く、さまざまな研究でその効果が確認されていますが、消化管への影響や顎骨壊死などの副作用にも注意が必要です。

次に、選択的エストロゲン受容体モジュレーター（SERM）は、エストロゲンの作用を模倣する作用を持ちながら、特定の組織においては逆に作用することができる薬剤です。代表的な薬剤にはラロキシフェンがあり、骨密度の増加を助ける一方で、乳がんのリスクを減少させる可能性があります。このように、SERMは骨粗鬆症の治療に加え、他のリスク要因への影響を考慮する際に有益です。

骨形成促進薬は、骨生成を促進する作用を持つ薬剤です。テリパラチドやアバロパラチドなどがその例であり、重篤な骨粗鬆症の患者に対して使用されます。これらの薬剤は、骨形成を刺激することで骨密度を増加させ、骨折リスクを低減する効果があります。ただし、長期間の使用による副作用や、治療コストの高さが課題となることがあります。

ホルモン療法も閉経後骨粗鬆症の治療に使用されることがあります。エストロゲン補充療法は、骨密度を保つためにエストロゲンのレベルを維持することを目的としており、特に骨粗鬆症のリスクが高い女性にとって効果的です。しかし、乳がんや心血管疾患のリスクが高くなる可能性があるため、使用には慎重な判断が必要です。

抗RANKL抗体は、最近の革新として注目されています。このクラスの薬剤、たとえばデノスマブは、骨吸収を抑えるメカニズムを持っており、高い効果が示されています。デノスマブは自宅での皮下注射が可能であり、患者の利便性が高い一方で、免疫系への影響や長期的な安全性の評価が行われています。

これらの治療薬の選択は、患者の年齢、性別、骨密度、既往歴、副作用のリスクなどを考慮して行われます。個々の患者に応じた最適な治療法を選択することが重要であり、またこれに関連する健康教育も必要です。

関連技術としては、骨密度測定の技術が挙げられます。DXA（デュアルエネルギーX線吸収測定法）は、骨密度を正確に測定するための標準的な方法とされています。また、骨粗鬆症の進行をモニタリングするためのバイオマーカーの研究も進んでおり、尿中や血中の特定の物質を測定して骨代謝の状態を評価する試みがあります。

閉経後骨粗鬆症は、生活の質に大きな影響を与える病気であり、その治療は多くの患者にとって欠かせないものです。治療薬の進歩によって、骨折のリスクを軽減することが可能になり、多くの患者がより充実した生活を送ることができるようになっています。今後も研究とともに新たな治療法の開発が期待されており、その成果はさらなる改善につながることが望まれます。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 閉経後骨粗鬆症治療薬の世界市場見通し2023年-2029年(Post Menopausal Osteoporosis Drug Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

閉経後骨粗鬆症治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp